A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 5, 1998, Pages 377-384

  Van Tellingen, O ^a   Punt, C J A ^b   Awada, A ^c   Wagener, D J T ^a,b   Piccart, M J ^c   Groot, Y ^d   Schaaf, L J ^e   Henrar, R E C ^d   Nooijen, W J ^a   Beijnen, J H ^f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JULES BORDET INSTITUTE   (Belgium)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PFIZER INC   (United States)

^f SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cyclopropylpyrroloindole prodrug; High performance liquid chromatography; Pharmacokinetics; Plasma clearance

Indexed keywords

CARZELESIN; DRUG METABOLITE; PRODRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZOFURANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; LYMPHOMA; METABOLIC CLEARANCE RATE;

EID: 15444356610     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050754     Document Type: Article

References (15)

1. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH (1994) Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst 86: 368
2. Houghton PJ, Cheshire PJ, Hallman JD II, Houghton JA (1995) Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 36: 45
3. Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA (1984) Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843
4. Jonkman-de Vries JD, Graaff-Teulen MJ de, Henrar RE, Kettenes-van den Bosch JJ, Bult A, Beijnen JH (1994) Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244). Invest New Drugs 12: 303
5. Lee CS, Gibson NW (1991) DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues U-73,975 and U-77,779. Cancer Res 51: 6586
6. Li LH, Kelly RC, Warpehoski MA, McGovren JP, Gebhard I, DeKoning TF (1991) Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest New Drugs 9: 137
7. Li LH, DeKoning TF, Kelly RC, Krueger WC, McGovren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD, Gebhard I (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904
8. McGovren JP, Clarke GL, Pratt EA, DeKoning TF (1984) Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot (Tokyo) 37: 63
9. Proost JH, Meijer DKF (1992) MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22: 155
10. Reynolds VL, Molineux IJ, Kaplan DJ, Swenson DH, Hurley LH (1985) Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 24: 6228
11. Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhart RH (1994) Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drugs 5: 10
12. Tellingen O van, Pels EM, Henrar RE, Schaaf LJ, Padbury GE, Beijnen JH, Nooijen WJ (1994) Fully automated high-performance liquid Chromatographiv method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. J Chromatogr 652: 51
13. Tellingen O van, Beijnen JH, Nooijen WJ, Van Oene S, Henrar REC, Schaaf LJ, Padbury GE (1994) Plasma pharmacokinetics of carzelesin (U-80,244) and metabolites (U-76,073, U-76,074) in mice and rats. Ann Oncol 5 [Suppl 5]: 171
14. Warpehoski MA, Hurley LH (1988) Sequence selectivity of DNA covalent modification. Chem Res Toxicol 1: 315
15. Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, De Jong J, Groot Y, Tellingen O van, Wanders J, Sessa C (1996) Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given on a daily x5 schedule. Clin Cancer Res 2: 1717